IMU-131 (HER-Vaxx)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for IMU-131 (HER-Vaxx), covering 2025-04-16 to 2025-05-11. Get the full timeline:
Most recent: Clinical Trial Update: A Study of IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON) [Phase 2]